Welcome to the UPF Digital Repository

Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR

Show simple item record

dc.contributor.author Dyrskjøt, Lars
dc.contributor.author Reinert, Thomas
dc.contributor.author Novoradovsky, Alexey
dc.contributor.author Zuiverloon, Tahlita CM
dc.contributor.author Beukers, Willemien
dc.contributor.author Zwarthoff, Ellen
dc.contributor.author Malats i Riera, Núria
dc.contributor.author Real, Francisco X.
dc.contributor.author Segersten, Ulrika
dc.contributor.author Malmström, Per-Uno
dc.contributor.author Knowles, Megan
dc.contributor.author Hurst, Carolyn
dc.contributor.author Sorge, Joseph
dc.contributor.author Borre, Michael
dc.date.accessioned 2015-06-02T08:11:23Z
dc.date.available 2015-06-02T08:11:23Z
dc.date.issued 2012
dc.identifier.citation Dyrskjot L, Reinert T, Novoradovsky A, Zuiverloon TCM, Beukers W, Zwarthoff E et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. British Journal of Cancer. 2012; 107: 1392-1398. DOI 10.1038/bjc.2012.412
dc.identifier.issn 0007-0920
dc.identifier.uri http://hdl.handle.net/10230/23714
dc.description.abstract Background: Multiple clinical risk factors and genetic profiles have been demonstrated to predict progression of non-muscle invasive bladder cancer; however, no easily clinical applicable gene signature has been developed to predict disease progression independent of disease stage and grade. Methods: We measured the intra-patient variation of an 88-gene progression signature using 39 metachronous tumours from 17 patients. For delineation of the optimal quantitative reverse transcriptase PCR panel of markers, we used 115 tumour samples from patients in Denmark, Sweden, UK and Spain. Results: Analysis of intra-patient variation of the molecular markers showed 71% similar classification results. A final panel of 12 genes was selected, showing significant correlation with outcome. In multivariate Cox regression analysis, we found that the 12-gene signature was an independent prognostic factor (hazard ratio=7.4 (95% confidence interval: 3.4–15.9), P<0.001) when adjusting for stage, grade and treatment. Independent validation of the 12-gene panel and the determined cut-off values is needed and ongoing. Conclusion: Intra-patient marker variation in metachronous tumours is present. Therefore, to increase test sensitivity, it may be necessary to test several metachronous tumours from a patient’s disease course. A PCR-based 12-gene signature significantly predicts disease progression in patients with non-muscle invasive bladder cancer.
dc.description.sponsorship The study was supported by The John and Birthe Meyer Foundation, the Danish Cancer Society, the Ministry of Technology and Science, and the Lundbeck Foundation. Furthermore, the research leading to these results has received funding from the European Community’s Seventh Framework program FP7/2007-2011 under grant agreement no. 201663.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Cancer Research UK
dc.relation.ispartof British Journal of Cancer. 2012;107:1392-8
dc.rights From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/
dc.subject.other Bufeta -- Càncer -- Aspectes moleculars
dc.subject.other Prognosi
dc.title Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1038/bjc.2012.412
dc.subject.keyword Bladder cancer
dc.subject.keyword PCR
dc.subject.keyword Heterogeneity
dc.subject.keyword Outcome
dc.subject.keyword Progression
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/201663
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking